Fresh analysis suggests that people who discontinue popular GLP-1 drugs like semaglutide or tirzepatide tend to recover shed pounds at a significantly accelerated pace than those who end traditional lifestyle plans.
Findings released in a major health publication shows that while obese individuals frequently drop a large proportion of their body weight while using the jabs, the mass comes back at an average rate of 0.8 kg per month once they quit.
"Users using such treatments should be cognizant of the danger of fast weight regain when the therapy is stopped," warns lead investigator Dr. Susan Jebb.
That rate of regain implies a reversion to original mass in about one and a half years.
Analyzing Approaches
The research, which looked at 37 of trials involving over 9,000 of participants, contrasted the results of GLP-1 agonists with conventional dieting.
Scientists emphasize that individuals who shed pounds through lifestyle changes alone typically have a less rapid creep back—approximately 100 grams monthly—after stopping.
Explaining the Fast Rebound
Experts believe the mode of action of the jabs is key to understanding the accelerated weight return.
The injections copy a body's own chemical called GLP-1, which moderates feelings of fullness.
"Long-term administration of GLP-1 levels several times higher than normal may cause the system to generate a reduced amount of its endogenous hormone, and may also reduce sensitivity to its effects," said Dr. Adam Collins, a nutrition researcher.
"Stopping of this GLP-1 'fix' results in hunger is no longer kept in check, making excessive eating much more probable."
An Ongoing Condition?
Medical guidelines advise the jabs for individuals with weight-linked health risks, alongside prescribed diet and exercise modifications.
Professionals say that, given the likelihood of weight regain, the therapy should be considered ongoing.
This perspective is echoed by pharmaceutical companies, who say that the findings "underscore the chronic nature of obesity," akin to managing diseases like diabetes.
Patient Accounts
Individuals who have come off the jabs describe a sudden return of hunger.
"It was like a trigger activating and I was suddenly ravenous," said a patient.
This challenge is exacerbated if patients have not established sustainable dietary or behavioural modifications during treatment.
Significant Use
Recent estimates indicate that a significant number of people in the UK have tried weight-loss jabs in the last 12 months, with desire remaining high.
- Use is higher among females than males.
- The middle-aged age group shows the highest usage rates.
- Many access the medications through private prescriptions rather than public health services.
Finally, clinicians emphasize that while these medications are potent tools for shedding pounds, they are not a permanent cure and lasting health benefits relies on integrated behavioural support.
